Electrophysiological Insights into Psychedelics: Implications for Trials

Understanding Electrophysiological Effects of Psychedelics

A systematic review published June 1, 2026 in PubMed consolidates current knowledge on how psychedelic drugs influence brain activity at the electrophysiological level. This review is pivotal for researchers and clinicians aiming to harness the therapeutic potential of psychedelics in clinical settings.

The review, available at PubMed, explores studies that used electroencephalography (EEG) and magnetoencephalography (MEG) to assess the brain's response to substances like psilocybin, LSD, and ayahuasca.

Mechanisms and Context

Psychedelics alter consciousness and perception, but mapping the precise electrophysiological mechanisms has required decades of careful measurement. The review highlights that psychedelics generally increase neural plasticity and connectivity, showing changes in brain wave patterns — particularly in the alpha and theta bands.

These changes are linked to the subjective experiences reported by users, such as altered perception and emotional release. Understanding these mechanisms is crucial for designing trials that aim to test psychedelics as treatments for mental health disorders.

EEG signatures across compounds: what the data show

Not all psychedelics produce identical EEG signatures. The table below summarizes the most replicated electrophysiological findings for the four compounds with the most published EEG data.

Key sources: Carhart-Harris et al. (PNAS 2016); Timmermann et al. (Scientific Reports 2019); Barker 2022 systematic review.

Implications for Clinical Trials

The insights from this review are invaluable for future clinical trials. Identifying electrophysiological biomarkers could enhance the precision of psychedelic-assisted therapies. Biomarkers can help predict therapeutic outcomes, tailor treatments to individual needs, and monitor intervention efficacy.

Such biomarkers could also facilitate regulatory approval by providing objective measures of drug effects — supporting the clinical development pipeline for psychedelics.

EEG biomarkers already in active use: trial-specific examples

Three features of the EEG literature are now influencing active trial design:

• Alpha suppression as a dose proxy. COMPASS Pathways used EEG-derived alpha power suppression in its COMP360 Phase 2b trial (n=233) as an objective pharmacodynamic marker to confirm drug exposure and distinguish therapeutic dose ranges — a strategy the FDA agreed to in a Special Protocol Assessment. This is the most advanced regulatory use of an EEG endpoint in a psychedelic trial to date.
• Neural complexity (Lempel-Ziv complexity). Carhart-Harris's group showed that psilocybin increases Lempel-Ziv complexity more than ketamine, proportionally to subjective intensity. Multiple trials are now pre-registering LZ complexity as a secondary endpoint to correlate with antidepressant response at follow-up.
• Gamma and theta coupling. In the Helus Pharma SPL026 Phase 2a (IV DMT; 32 participants), an EEG sub-study tracked theta/gamma ratio as a potential biomarker for treatment response in MDD. If validated, this would be the first regulatory submission using a psychedelic-specific EEG endpoint in a pivotal trial context.

Understanding which EEG feature maps to therapeutic outcome — rather than to subjective intensity alone — is the key unsolved question in this field.

Risks and Unknowns

Despite the promising insights, several risks and unknowns remain. The variability in individual responses to psychedelics poses a challenge for standardizing treatment protocols. The long-term effects of altered brain activity patterns are not fully understood, necessitating further research.

There is also a need to explore potential adverse effects in vulnerable populations and develop guidelines for safe administration in clinical settings.

Practical limitations of EEG in psychedelic research

• Motion artifact. High-dose psychedelic sessions involve body movement, tremor, and eye movements that contaminate EEG channels. Even with ICA-based artifact rejection, artifact-free epochs at peak drug effect may be too short to compute reliable spectral estimates.
• Blinding confound. Alpha suppression is visible in the raw EEG trace within minutes of dosing. An EEG operator in the room is de facto unblinded to dose condition — meaning EEG endpoints must be pre-specified and auto-scored to carry credibility.
• No accepted regulatory benchmark. There is no FDA or EMA guidance specifying which EEG feature constitutes an approvable biomarker for a psychedelic indication. COMPASS's use of alpha suppression as a pharmacodynamic marker is exploratory, not a regulatory requirement. Until a biomarker is formally "qualified," it remains a secondary endpoint, not a basis for approval.
• Inter-individual variability. Baseline alpha power varies by up to 10 dB across healthy adults. Normalizing to individual baseline is essential but not uniformly done across published studies, limiting cross-study comparisons.

Looking Forward

The review underscores the importance of interdisciplinary collaboration in advancing psychedelic research. Neuroscientists, clinicians, and policymakers must work together to translate these electrophysiological insights into effective and safe therapeutic applications.

Future research should focus on expanding the understanding of how different psychedelics affect brain activity and identifying more precise biomarkers. This could pave the way for personalized psychedelic therapies and potentially revolutionize treatment approaches for mental health disorders.

The next critical milestone is the full publication of the SPL026 Phase 2a EEG sub-study and the COMPASS COMP360 EEG biomarker analysis. If either demonstrates that a pre-session or early-session EEG feature predicts 3-month remission, the field will have its first actionable electrophysiological tool for patient selection — a development that could materially accelerate regulatory timelines for psilocybin and DMT-based therapies.